The mysteries of
menopause solved
Your body naturally produces a family of hormones called estrogen—you’ve probably heard of it1,2
We’d list them all, but seriously—there’s not enough room.
There are dozens of recognized symptoms of menopause.8
In one study, women were interviewed about the ways VMS impacted their quality of life.11,*
Another study assessed the effect of VMS on women's work life.12,†
reported that VMS symptoms negatively impacted their performance at work12
*In-person interviews were conducted for a total of 16 women in the United States aged 40 to 64 years who were experiencing ≥35 moderate to severe hot flashes and/or night sweats per week.11
†Questionnaires were collected from 407 women, of whom 339 were aged 45 to 64 years and were experiencing menopause symptoms or had already gone through menopause. Participants rated the extent to which 10 menopause symptoms affected their work.12
Menopause treatments—a hot topic, and a confusing one
Actor portrayals.
Actor portrayals. MHT: Let’s talk about it
MHT is the first choice of many experts to treat menopause symptoms like VMS. In 2026, the FDA announced that MHTs like BIJUVA® are a valuable choice for women who are younger than 60 years old or who entered menopause within the past 10 years.14,15
Are you looking for proven relief from VMS with a well-documented safety profile and the simplicity of a once-daily capsule?16
References: 1. Crandall CJ, Mehta JM, Manson JE. Management of menopausal symptoms: a review. JAMA. 2023;329(5):405-420. 2. Panay N, Ang SB, Cheshire R, Goldstein SR, Maki P, Nappi RE; International Menopause Society Board. Menopause and MHT in 2024: addressing the key controversies – an International Menopause Society White Paper. Climacteric. 2024;27(5):441-457. 3. Stute P, Marsden J, Salih N, Cagnacci A. Reappraising 21 years of the WHI study: putting the findings in context for clinical practice. Maturitas. 2023;174:8-13. 4. Zhu J, Zhou Y, Jin B, Shu J. Role of estrogen in the regulation of central and peripheral energy homeostasis: from a menopausal perspective. Ther Adv Endocrinol Metab. 2023;14:20420188231199359. 5. Aryan L, Younessi D, Zargari M, et al. The role of estrogen receptors in cardiovascular disease. Int J Mol Sci. 2020;21(12):4314. 6. Chen P, Li B, Ou-Yang L. Role of estrogen receptors in health and disease. Front Endocrinol (Lausanne). 2022;13:839005. 7. Maki PM, Jaff NG. Brain fog in menopause: a health-care professional’s guide for decision-making and counseling on cognition. Climacteric. 2022;25(6):570-578. 8. Aras SG, Grant AD, Konhilas JP. Clustering of > 145,000 symptom logs reveals distinct pre, peri, and menopausal phenotypes. Sci Rep. 2025;15(1):640. 9. Wright AC, Beaudoin FL, McQueen RB, et al. The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: a summary from the Institute for Clinical and Economic Review’s Midwest Public Advisory Council. J Manag Care Spec Pharm. 2023;29(6):692-698. 10. Mirkin S, Graham S, Revicki DA, Bender RH, Bernick B, Constantine GD. Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone. Menopause. 2019;26(6):637-642. 11. English M, Stoykova B, Slota C, et al. Qualitative study: burden of menopause-associated vasomotor symptoms (VMS) and validation of PROMIS Sleep Disturbance and Sleep-Related Impairment measures for assessment of VMS impact on sleep. J Patient Rep Outcomes. 2021;5(1):37. 12. O’Neill MT, Jones V, Reid A. Impact of menopausal symptoms on work and careers: a cross-sectional study. Occup Med (Lond). 2023;73(6):332-338. 13. Panay N, Fenton A, Hamoda H, et al; IMS Recommendations Writing Group. International Menopause Society (IMS) recommendations and key messages on women’s midlife health and menopause. Climacteric. 2025;28(6):634-656. 14. North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. 15. FDA approves labeling changes to menopausal hormone therapy products. News release. US Food and Drug Administration. February 12, 2026. Accessed July 14, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products 16. BIJUVA [package insert]. Raleigh, NC: Mayne Pharma. February 2026.
